Related Experiment Videos
The complement cascade in Alzheimer's disease.
1Gliatech Inc., Cleveland, Ohio 44122, USA.
Drug News & Perspectives
|December 24, 2004
Summary
Alzheimer's disease (AD) involves activated glial cells releasing complement proteins that may damage brain tissue. Therapies could target these proteins to slow AD progression without harming the immune system.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Activated glial cells in Alzheimer's disease (AD) release molecules contributing to pathology.
- Complement proteins are key players, known for inflammation and potential host tissue damage.
Purpose of the Study:
- To strengthen the hypothesis that complement activation contributes to AD neuropathology.
- To identify potential therapeutic agents to attenuate complement activity in AD.
Main Methods:
- Reviewing evidence on complement protein association with senile plaques in AD brain.
- Investigating the role of amyloid-beta (Abeta) in activating the complement system.
Main Results:
- Early complement pathway components are found with senile plaques in AD brain.
- Evidence suggests Abeta activates complement, potentially through Abeta-C1q binding.
Conclusions:
- Demonstrating terminal complement activation products in AD brain is crucial for understanding disease mechanisms.
- Developing drugs to modulate complement activity in AD is a promising therapeutic avenue.